The FDA has approved an update to the drug label for Reclast (zoledronic acid) so that health care professionals are better informed about the risk of renal failure associated with use of the drug.

Risk factors for renal failure including underlying moderate to severe renal impairment, use of nephrotoxic or diuretic medications at the same time as Reclast, or severe dehydration occurring before or after Reclast is given.

Renal toxicity already has been addressed in the labeling for Zometa, another brand of zoledronic acid.

Continue Reading